About NeuroOne Medical Technologies Corporation
https://n1mtc.comNeuroOne Medical Technologies Corporation operates as a medical technology company.
CEO
David A. Rosa
Compensation Summary
(Year 2024)
Salary $521,856
Stock Awards $683,402
Option Awards $562,175
Incentive Plan Pay $228,312
Total Compensation $1,995,745
Industry Medical - Devices
Sector Healthcare
Went public March 15, 2018
Method of going public IPO
Full time employees 17
Split Record
| Date | Type | Ratio |
|---|---|---|
| 2021-04-01 | Reverse | 1:3 |
ETFs Holding This Stock
Summary
Total 11
Showing Top 1 of 11
Ratings Snapshot
Rating : C
Discounted Cash Flow 1
Return On Equity 1
Return On Assets 1
Debt To Equity 4
Price To Earnings 1
Price To Book 2
Overall Score 2
Price Target
Target High $3
Target Low $3
Target Median $3
Target Consensus $3
Institutional Ownership
BLEICHROEDER LP
Shares:4M
Value:$3.48M
SIO CAPITAL MANAGEMENT, LLC
Shares:2.36M
Value:$2.05M
BARD ASSOCIATES INC
Shares:1.85M
Value:$1.61M
Summary
% Of Shares Owned 28.47%
Total Number Of Holders 36
Showing Top 3 of 36
Market Cap $44.99 M
52w High $1.39
52w Low $0.40
P/E -9.67
Volume 500.51K
Outstanding Shares 50.41M
About NeuroOne Medical Technologies Corporation
https://n1mtc.comNeuroOne Medical Technologies Corporation operates as a medical technology company.
Income Statement
| Period | Revenue | Operating Expense | Net Income | Net Profit Margin | Earnings Per Share | EBITDA |
|---|---|---|---|---|---|---|
| Q4-2025 | $2.74M ▲ | $2.9M ▲ | $-1.62M ▼ | -59.08% ▲ | $-0.04 ▼ | $-1.55M ▼ |
| Q3-2025 | $1.7M ▲ | $2.8M ▼ | $-1.5M ▲ | -88.49% ▲ | $-0.03 ▲ | $-1.42M ▲ |
| Q2-2025 | $1.39M ▼ | $3.45M ▲ | $-2.27M ▼ | -163.76% ▼ | $-0.07 ▼ | $-2.2M ▼ |
| Q1-2025 | $3.27M ▲ | $215.68K ▼ | $1.79M ▲ | 54.53% ▲ | $0.06 ▼ | $2.18M ▲ |
| Q4-2024 | $272.28K | $2.96M | $-3.35M | -1.23K% | $0.34 | $-2.95M |
Balance Statement
| Period | Cash & Short-term | Total Assets | Total Liabilities | Total Equity |
|---|---|---|---|---|
| Q4-2025 | $6.57M ▼ | $10.79M ▼ | $3.71M ▲ | $7.07M ▼ |
| Q3-2025 | $8.04M ▲ | $10.82M ▲ | $2.64M ▼ | $8.18M ▲ |
| Q2-2025 | $1.32M ▲ | $4.46M ▼ | $3.33M ▼ | $1.13M ▼ |
| Q1-2025 | $1.13M ▼ | $6.49M ▲ | $3.56M ▼ | $2.94M ▲ |
| Q4-2024 | $1.46M | $5.37M | $4.55M | $822.01K |
Cash Flow Statement
| Period | Net Income | Cash From Operations | Cash From Investing | Cash From Financing | Net Change | Free Cash Flow |
|---|---|---|---|---|---|---|
| Q4-2025 | $-1.62M ▼ | $-1.53M ▼ | $-10.61K ▲ | $-7.82M ▼ | $-1.47M ▼ | $-1.54M ▼ |
| Q3-2025 | $-1.5M ▲ | $-1.46M ▼ | $-43.55K ▼ | $8.23M ▲ | $6.72M ▲ | $-1.51M ▼ |
| Q2-2025 | $-2.27M ▼ | $-56.14K ▼ | $-3.17K ▲ | $245.22K ▲ | $185.9K ▲ | $-59.31K ▼ |
| Q1-2025 | $1.79M ▲ | $208.05K ▲ | $-24.42K ▲ | $-509.32K ▼ | $-325.69K ▼ | $183.63K ▲ |
| Q4-2024 | $-3.35M | $-2.67M | $-36.91K | $2.54M | $-159.94K | $-2.7M |
CEO
David A. Rosa
Compensation Summary
(Year 2024)
Salary $521,856
Stock Awards $683,402
Option Awards $562,175
Incentive Plan Pay $228,312
Total Compensation $1,995,745
Industry Medical - Devices
Sector Healthcare
Went public March 15, 2018
Method of going public IPO
Full time employees 17
Split Record
| Date | Type | Ratio |
|---|---|---|
| 2021-04-01 | Reverse | 1:3 |
ETFs Holding This Stock
Summary
Total 11
Showing Top 1 of 11
Ratings Snapshot
Rating : C
Discounted Cash Flow 1
Return On Equity 1
Return On Assets 1
Debt To Equity 4
Price To Earnings 1
Price To Book 2
Overall Score 2
Price Target
Target High $3
Target Low $3
Target Median $3
Target Consensus $3
Institutional Ownership
BLEICHROEDER LP
Shares:4M
Value:$3.48M
SIO CAPITAL MANAGEMENT, LLC
Shares:2.36M
Value:$2.05M
BARD ASSOCIATES INC
Shares:1.85M
Value:$1.61M
Summary
% Of Shares Owned 28.47%
Total Number Of Holders 36
Showing Top 3 of 36